JP2024511079A - 抗セラミド抗体による創傷治癒の強化 - Google Patents

抗セラミド抗体による創傷治癒の強化 Download PDF

Info

Publication number
JP2024511079A
JP2024511079A JP2023557734A JP2023557734A JP2024511079A JP 2024511079 A JP2024511079 A JP 2024511079A JP 2023557734 A JP2023557734 A JP 2023557734A JP 2023557734 A JP2023557734 A JP 2023557734A JP 2024511079 A JP2024511079 A JP 2024511079A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antigen
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511079A5 (enExample
Inventor
リチャード コールスニック
ジュリア ブシク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Michigan State University MSU
Original Assignee
Michigan State University MSU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan State University MSU filed Critical Michigan State University MSU
Publication of JP2024511079A publication Critical patent/JP2024511079A/ja
Publication of JP2024511079A5 publication Critical patent/JP2024511079A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023557734A 2021-03-16 2022-03-15 抗セラミド抗体による創傷治癒の強化 Pending JP2024511079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161758P 2021-03-16 2021-03-16
US63/161,758 2021-03-16
PCT/US2022/020385 WO2022197703A1 (en) 2021-03-16 2022-03-15 Wound healing enhancement with anti-ceramide antibodies

Publications (2)

Publication Number Publication Date
JP2024511079A true JP2024511079A (ja) 2024-03-12
JP2024511079A5 JP2024511079A5 (enExample) 2025-09-03

Family

ID=83321040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557734A Pending JP2024511079A (ja) 2021-03-16 2022-03-15 抗セラミド抗体による創傷治癒の強化

Country Status (10)

Country Link
US (1) US20240158487A1 (enExample)
EP (1) EP4308231A4 (enExample)
JP (1) JP2024511079A (enExample)
KR (1) KR20230162788A (enExample)
CN (1) CN117320750A (enExample)
BR (1) BR112023018758A2 (enExample)
CA (1) CA3212333A1 (enExample)
IL (1) IL305920A (enExample)
MX (1) MX2023010858A (enExample)
WO (1) WO2022197703A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523970A (ja) * 2012-05-25 2015-08-20 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病の治療方法
JP2017527544A (ja) * 2014-08-07 2017-09-21 メモリアル スローン−ケタリング キャンサー センター 抗セラミド抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (en) * 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
WO2010027802A2 (en) * 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
EP4121110A4 (en) * 2020-03-18 2024-06-12 Memorial Sloan Kettering Cancer Center ANTI-CERAMIDE ANTIBODIES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523970A (ja) * 2012-05-25 2015-08-20 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病の治療方法
JP2017527544A (ja) * 2014-08-07 2017-09-21 メモリアル スローン−ケタリング キャンサー センター 抗セラミド抗体

Also Published As

Publication number Publication date
EP4308231A1 (en) 2024-01-24
EP4308231A4 (en) 2025-01-29
WO2022197703A1 (en) 2022-09-22
MX2023010858A (es) 2023-11-23
BR112023018758A2 (pt) 2023-11-28
KR20230162788A (ko) 2023-11-28
IL305920A (en) 2023-11-01
US20240158487A1 (en) 2024-05-16
CN117320750A (zh) 2023-12-29
CA3212333A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
RU2704999C2 (ru) Способ лечения кожной инфекции путем введения антагониста il-4r
JP2024038234A (ja) Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
KR102887037B1 (ko) 호중구 질환을 치료하는 방법
CA2944605C (en) Methods of treating nail and scalp psoriasis
JP2021193121A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2022126791A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
EP4670788A2 (en) TREATMENT METHODS FOR PSORIASIS USING IL-17 ANTAGONISTS
US12083161B2 (en) Treating IgE-mediated allergic diseases
TWI847170B (zh) 用於治療異位性皮炎之il-13抗體
KR20230004638A (ko) 화농성 한선염의 치료
IL324054A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
US20240158487A1 (en) Wound healing enhancement with anti-ceramide antibodies
RU2828020C2 (ru) Способы лечения атопического дерматита посредством введения антагониста il-4r
RU2800765C2 (ru) ЛЕЧЕНИЕ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
CA3117142C (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
RU2772202C2 (ru) Лечение гнойного гидраденита
EP4704974A1 (en) Il-22r antibody for use in treating atopic dermatitis
WO2025124481A1 (zh) Tfpi抗体用于治疗血友病
HK40048904B (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
HK40048904A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
EA049484B1 (ru) Антитела против хемокинов pan-elr+ cxc для лечения гнойного гидраденита
EA044851B1 (ru) Антитела против хемокинов pan-elr+ cxc для лечения гнойного гидраденита

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260302